» Articles » PMID: 20207492

Stereotactic Body Radiotherapy for Patients with Unresectable Primary Hepatocellular Carcinoma: Dose-volumetric Parameters Predicting the Hepatic Complication

Overview
Specialties Oncology
Radiology
Date 2010 Mar 9
PMID 20207492
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To identify the parameters that predict hepatic toxicity and deterioration of hepatic function.

Materials And Methods: A total of 47 patients with small unresectable primary hepatocellular carcinoma received hypofractionated stereotactic body radiotherapy (SBRT) using the CyberKnife. Of those, 36 patients received no other local treatments that could influence hepatic toxicity at least for 3 months after the completion of SBRT. The gross tumor volume (GTV) was 18.3 ± 15.9 cm(3) (range, 3.0-81.3 cm(3)), and the total dose administered was 30-39 Gy (median, 36 Gy). To assess the deterioration of hepatic function, we evaluated the presence or absence of the progression of Child-Pugh class (CP class). To identify the parameters of predicting the radiation-induced hepatic toxicity and deterioration of the hepatic function, several clinical and dose-volumetric parameters were evaluated.

Results: Of 36 patients, 12 (33%) developed Grade 2 or higher hepatic toxicity and 4 (11%) developed progression of CP class. The multivariate analysis showed that the only significant parameter associated with the progression of CP class was the total liver volume receiving a dose less than 18 Gy (<18 Gy).

Conclusions: The progression of CP class after SBRT limits other additional local treatments and also reflects the deterioration of hepatic function. Therefore, it would be important to note that the presence or absence of the progression of CP class is a dose-limiting factor. The total liver volume receiving <18 Gy should be greater than 800 cm(3) to reduce the risk of the deterioration of hepatic function.

Citing Articles

Prognostic nomogram of overall survival for radiation therapy in hepatocellular carcinoma: a population study based on the SEER database and an external cohort.

Chen L, Wu Q, Fu J, Jiang M, Qiu J, Tao J Front Oncol. 2024; 14:1371409.

PMID: 39286027 PMC: 11402715. DOI: 10.3389/fonc.2024.1371409.


Evaluation of liver segmental dose threshold for hepatocyte regeneration following liver stereotactic body radiation therapy.

George K, Chopra S, Rajamanickam K, Joshi K, Swamidas J, Shetty N Indian J Med Res. 2024; 159(2):232-240.

PMID: 38442296 PMC: 11050757. DOI: 10.4103/ijmr.ijmr_1171_21.


Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study.

Wu Q, Wang Y, Wei Y, Yang Z, Chen K, Li J Jpn J Clin Oncol. 2024; 54(6):699-707.

PMID: 38376811 PMC: 11144290. DOI: 10.1093/jjco/hyae024.


Effectiveness of Robotic Stereotactic Radiotherapy in Patients Undergoing Re-irradiation: A Review.

Yoosuf A, Alshehri S, Abdul Aziz M, Mansor S, Appalanaido G, Alqathami M Cureus. 2023; 15(8):e43500.

PMID: 37719625 PMC: 10500384. DOI: 10.7759/cureus.43500.


Feasibility and dosimetric evaluation of single- and multi-isocentre stereotactic body radiation therapy for multiple liver metastases.

Tang C, Gong C, Liu B, Guo H, Dai Z, Yuan J Front Oncol. 2023; 13:1144784.

PMID: 37188200 PMC: 10175834. DOI: 10.3389/fonc.2023.1144784.